文献速递生殖医学

开始生育治疗的夫妇活产长期预后

The long-term prognosis for live birth in couples initiating fertility treatments.
PubMed 文献 · Hum Reprod · 2017-01-01

这项丹麦全国性登记队列研究纳入2007—2010年在公立和私立诊所使用同源配子开始生育治疗的全部女性,随访2年(19884对)、3年(14445对)和5年(5165对)至首次活产。5年总活产率随女性年龄变化,<35岁为80%、35—39岁为60%、≥40岁为26%,总体14%自然受孕,以IUI起始者中三分之一经该治疗分娩。

要点

  • 5年总活产率:<35岁80%、35—39岁60%、≥40岁26%。
  • 5年内因治疗活产:<35岁64%、35—39岁49%、≥40岁16%。
  • IUI起始者5年内35%经IUI分娩、17%自然受孕分娩。

核心结论

  • 5年总活产率受女性年龄强烈影响,范围从<35岁的80%到≥40岁的26%,总体14%的夫妇自然受孕。
  • 以IUI起始治疗的夫妇中三分之一经该治疗分娩。

研究设计与样本

  • 基于丹麦全国登记处的队列研究,纳入2007—2010年在公立和私立诊所使用同源配子开始生育治疗的全部女性。
  • 通过丹麦ART登记处识别女性并与医学出生登记处交叉链接识别活产。
  • 随访2年(N=19884)、3年(N=14445)和5年(N=5165)或至首次活产。
  • 从首次治疗周期起估算2、3、5年累积活产率,纳入所有女性包括退出者。
  • 按首次治疗类型(ART/IUI)、受孕方式(ART/IUI/自然受孕)和女性年龄分层。

主要发现

  • 5年内因治疗活产:<35岁(N=3553)64%、35—39岁(N=1156)49%、≥40岁(N=451)16%。
  • 5年内自然受孕分娩:<35岁16%、35—39岁11%、≥40岁10%,合计5年总活产率分别为80%、60%、26%。
  • 以IUI起始治疗者(N=3028)5年内35%经IUI分娩、24%转ART后分娩、17%自然受孕分娩。
  • 以ART起始治疗者(N=2137)5年内53%经ART分娩、11%自然受孕分娩、0.6%经IUI分娩。

临床怎么用

  • 作者认为结果可在治疗开始时为夫妇提供易懂的按年龄分层的预后。

局限性

  • 与无国家覆盖治疗的国家相比,活产率很可能更高,结果受法律和法规影响。
  • 缺乏治疗前不孕持续时间的信息。
  • 未来前瞻性干预研究应关注期待管理的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the long-term chances of having a child for couples starting fertility treatments and how many conceive with ART, IUI and without treatment? SUMMARY ANSWER: Total 5-year live birthrates were strongly influenced by female age and ranged from 80% in women under 35-26% in women ≥40 years, overall, 14% of couples conceived naturally and one-third of couples starting treatments with intrauterine insemination delivered from that treatment. WHAT IS KNOWN ALREADY: Few studies report success rates in fertility treatments across a couple's complete fertility treatment history, across clinics, evaluating live births after insemination, ART and natural conceptions. STUDY DESIGN, SIZE, DURATION: This register-based national cohort study from Denmark includes all women initiating fertility treatments in public and private clinics with homologous gametes in 2007-2010. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women were identified in the Danish ART Registry and were cross-linked with the Medical Birth Registry to identify live births. Subfertile couples were followed 2 years (N = 19 884), 3 years (N = 14 445) and 5 years (N = 5165), or until their first live birth. Cumulative live birthrates were estimated 2, 3 and 5 years from the first treatment cycle, in all women, including drop-outs. Birthrates were stratified by type of first treatment (ART/IUI), mode of conception (ART/IUI/natural conception) and female age. MAIN RESULTS AND THE ROLE OF CHANCE: Within 5 years, in women aged <35 years (N = 3553), 35-39 years (N = 1156) and ≥40 years (N = 451), a total of 64%, 49% and 16% had a live birth due to treatment, respectively. Additionally, in women aged < 35 years, 35-39 years and ≥40 years, 16%, 11% and 10% delivered after natural conception, yielding total 5-year birthrates of 80%, 60% and 26%. In women starting treatments with IUI (N = 3028), 35% delivered after IUI within 5 years, 24% delivered after shift to ART treatments and 17% delivered after natural conception. Within 5 years from starting treatments with ART (N = 2137), 53% delivered after ART, 11% delivered after natural conception and 0.6% delivered after IUI. LIMITATIONS, REASONS FOR CAUTION: Birthrates are most likely higher compared to countries without national coverage of treatments and results are influenced by laws and regulations. Information on duration of infertility prior to treatment was not available. Future prospective intervention studies should focus on the role of expectant management. WIDER IMPLICATIONS OF THE FINDINGS: Our results can provide couples with a comprehensible age-stratified prognosis at start of treatment. STUDY FUNDING/COMPETING INTEREST(S): This study was unconditionally funded by Ferring Pharmaceuticals and the Augustinus foundation. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: S.S.M. received an unconditional grant from Ferring Pharmaceuticals; A.A.H. has received personal fees from Ferring Pharmaceuticals not related to this work; A.N.A. reports grants and personal fees from Ferring Pharmaceuticals, personal fees from Merck Serono, grants and personal fees from MSD, outside the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. TRIAL REGISTRATION NUMBER: The study was approved by the Danish Data Protection Agency (J.nr. 2012-41-1330).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Malchau SS, Henningsen AA, Loft A, et al. The long-term prognosis for live birth in couples initiating fertility treatments. Hum Reprod. 2017. PMID: 28472455. doi:10.1093/humrep/dex096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。